d13

D13 is an acylhydrazone antifungal.1 It is active against C. neoformans in vitro (MIC80 = 0.06 μg/ml). D13 (20 mg/kg per day, p.o.) increases survival in mouse models of C. neoformans, C. albicans, or A. fumigatus infection. |1. Lazzarini, C., Haranahalli, K., Rieger, R., et al. Acylhydrazones as antifungal agents targeting the synthesis of fungal sphingolipids. Antimicrob. Agents Chemother. 62(5), e00156-00118 (2018).

Alachlo-d13 (2,6-diethylphenyl-d13) is a deuterated compound of Alachlo.

Choline-d13 Bromide (N,N,N-trimethyl-d9; 1,1,2,2-d4) is a deuterated compound of Choline Bromide. Choline Bromide has a CAS number of 1927-06-6.

Lusutrombopag-d13 is a deuterated compound of Lusutrombopag. Lusutrombopag has a CAS number of 1110766-97-6. Lusutrombopag is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery.

The KD values of D13-9001 in Escherichia coli and Pseudomonas aeruginosa were 1.15μM and 3.57μM, respectively. D13-9001 has antibiotic activity. It is an effective AcrB (AcrAB-TolC efflux pump subunit) and MexB (MexAB-OprM efflux pump subunit) inhibitor.

TD139 is a small molecule inhibitor of inhaled galectin-3 (Gal-3) with potential anti-fibrotic activity, commonly used in the study of idiopathic pulmonary fibrosis.

MD13 is a macrophage migration inhibitor (MIF) oriented PROTAC (Ki value: 71 nM). MD13 can be used to study cancer.

HDAC CD13-IN-1 (Compound 12) is an inhibitor of both HDAC and CD13, with IC50 values of 0.34 μM for hCD13, 0.53 μM for porcine CD13, and 0.03, 0.06, and 0.02 μM for HDAC1, HDAC2, and HDAC3, respectively. This compound effectively suppresses proliferation and induces apoptosis in MV4-11, K562, Jeko-1, and HL60 cancer cells, with IC50 ranges of 0.25-2.04 μM, and demonstrates capabilities in hindering metastasis and invasion [1].

NVP-BBD130 is a stable, ATP-competitive, potent, orally active inhibitor of PI3K and mTOR.

AZD1386 is a TRPV1 antagonist. AZD1386 acts as a competitive antagonist at the channel's capsaicin binding site.

The isotype control subtype of anti-mouse 4-1BB CD137(3H3) antibody is Rat IgG2a.

Anti-mouse 4-1BB CD137(1D8) antibody, targeting 4-1BB CD137.

MIF degrader MD13 is involved in protein-protein interactions that play key roles in inflammation and cancer. Current strategies to develop small molecule modulators of MIF functions are mainly restricted to the MIF tautomerase active siteMIF degrader MD13. MD13 also exhibits antiproliferative effect in a 3D tumor spheroid model. In conclusion, we describe the first MIF-directed PROTAC (MD13) as a research tool, which also demonstrates the potential of PROTACs in cancer therapy.

AZD1390 is an exceptionally potent inhibitor of ATM in cells (IC50: 0.78 nM) with >10,000-fold selectivity over closely related members of the PIKK family of enzymes.

Anti-mouse 4-1BB CD137(MU137-1) antibody, targeting 4-1BB CD137.

Anti-mouse OX40 CD134 antibody is a kind of antibody that can be used for ELISA, Flow cytometry and other related research.

Aminopeptidase N Ligand (CD13) NGR peptide, a polypeptide that targets CD13, functions as a carrier for mediating intracellular transmission and is commonly utilized in cancer research [1][2].

ZDLD13 is a β-carboline that exhibits potent anti-HCT116 activity inclusive of inhibition of invasion and migration, inhibition of colony formation, inducing of apoptosis as well as arresting of G1 phase in cell cycle. ZDLD13 is an orally active and selective inhibitor of CDK4 CycD3 (IC 50 = 0.38 μM) which exhibits significant inhibition of tumor growth in HCT116 tumor xenograft model [1].

The Anti-Mouse4-1BB CD137 Antibody (LOB12.3) is a mouse-derived antibody characterized by its rat IgG1 kappa isotype and specifically targets 4-1BB CD137. Its isotype control is the Rat IgG1 kappa, Isotype Control.

HIF-1α-IN-7 (Compound D13) serves as a potent inhibitor of HIF-1α and exhibits neuroprotective activity. This compound is applicable for research in Alzheimer's disease [1].

SHP2-IN-33 (Compound D13) is an allosteric inhibitor of SHP2, exhibiting an IC50 of 1.2 μM against SHP2. It demonstrates an antiproliferative IC50 of 38 μM in Huh7 cells by blocking the G0 G1 cell cycle, inducing apoptosis (Apoptosis), and inhibiting the MAPK signaling pathway. In a Huh7 xenograft mouse model, SHP2-IN-33 shows significant antitumor activity and favorable pharmacokinetic properties, including 54% oral bioavailability and a half-life of 10.57 hours. SHP2-IN-33 holds potential for research involving SHP2-associated tumor diseases.